Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 3
2(50.0%)
4Total
Phase 1(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02024152Phase 1Completed

Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg

Role: lead

NCT02045524Phase 1Completed

A Pilot Single Dose Crossover Pharmacokinetics Study Of JDP-205 Injection, 10 mg, In Healthy Male And Female Volunteers

Role: lead

NCT02023164Phase 3Completed

Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria

Role: lead

NCT02935699Phase 3Completed

Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria

Role: lead

All 4 trials loaded